Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

STRO-002

Phase 1Small molecule

SSutro Biopharma, Inc.

STRO-002 is one of 77 small molecule programs targeting Ovarian Cancer. It is currently in Phase 1.

2

Indications

3

Total Trials

1

Active Trials

76

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ovarian CancerActive, not recruiting

Endometrial CancerActive, not recruiting

Ovarian CancerPhase 1

Active, not recruiting

Endometrial CancerPhase 1

Active, not recruiting

Competition

Competitive Landscape

836 competitors in Ovarian Cancer

#DrugCompanyPhaseTrials

Imfinzi

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Lynparza

RRisen (Suzhou) Pharma Tech Co., Ltd.

Piqray

Liposomal Doxorubicin

Pamiparib

Salvage Chemotherapy

Karenitecin

BBioNumerik Pharmaceuticals, Inc.

Azenosertib

KK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.

JSKN003

JJiangsu Alphamab Biopharmaceuticals Co., Ltd

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1/2Recruiting

Ovarian Cancer

NCT06238687

Clinical

Trials by Indication[1]

Ovarian Cancer2 trials

A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer

Terminated·SSutro Biopharma, Inc.·Phase 1·NCT05200364·58 enrolled

A Study of STRO-002 in Chinese Adults With Epithelial Ovarian Cancer and Other Advanced Malignant Solid Tumors

Recruiting· Tasly Pharmaceutical Group Co., Ltd logo

Tasly Pharmaceutical Group Co., Ltd·Phase 1/2·NCT06238687·132 enrolled

Endometrial Cancer1 trial

Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers

Completed·SSutro Biopharma, Inc.·Phase 1·NCT03748186·136 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for STRO-002. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — STRO-002 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for STRO-002. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sutro Biopharma, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: SSutro Biopharma, Inc.

Related News